Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Demonstrated ...
Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.
Jonathan Wygant, VP at Veracyte (NASDAQ: VCYT ), executed a substantial insider sell on November 12, according to an SEC ...
Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a ...
-- 63% complete response (CR) rate at any time (n=62); -- 56% CR rate at 3 months (n=62); -- 62% CR rate at 6 months (n=37), with 4 patients having successfully converted to CR post reinduction; and - ...
DOUBLED over in pain, Amy Braid fought back tears as another wave of agonising cramps radiated through her body. But she wasn ...
BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ ...
Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety ...
The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...
Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 134.1 million in the third quarter of 2025 (Q3 2024: NOK 120.1 million) ...
Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...
Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash equivalents of $76.9 million as of September 30, 2025 PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback